In the last three months, 13 analysts have published ratings on Hims & Hers Health (NYSE:HIMS), offering a diverse range of perspectives from bullish to bearish.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $24.33, with a high estimate of $60.00 and a low estimate of $13.25. Experiencing a 30.58% decline, the current average is now lower than the previous average price target of $35.05.

Interpreting Analyst Ratings: A Closer Look

A clear picture of Hims & Hers Health's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Hims & Hers Health. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Hims & Hers Health compared to the broader market.
• Price Targets: Understanding forecasts, analysts offer estimates for Hims & Hers Health's future value. Examining the current and prior targets provides insight into analysts' changing expectations.

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Hims & Hers Health's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on Hims & Hers Health analyst ratings.

Unveiling the Story Behind Hims & Hers Health

Hims & Hers Health Inc operates telehealth platforms, providing access to treatments for various chronic conditions, including those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. The company connects patients to licensed healthcare professionals who can prescribe medications, with prescriptions fulfilled online through licensed pharmacies. In addition, it offers access to various non-prescription health and wellness products. Through the Hims & Hers mobile applications, the company also offers access to educational programs, wellness content, community support, and other services that promote lifelong health and wellness. Geographically, it derives maximum revenue from the USA.

Hims & Hers Health's Economic Impact: An Analysis

Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.

Revenue Growth: Hims & Hers Health's remarkable performance in 3M is evident. As of 31 December, 2025, the company achieved an impressive revenue growth rate of 28.41%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 3.33%, the company may need to address challenges in effective cost control.

Return on Equity (ROE): Hims & Hers Health's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.67% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): Hims & Hers Health's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.94%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: Hims & Hers Health's debt-to-equity ratio surpasses industry norms, standing at 2.07. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

How Are Analyst Ratings Determined?

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga's automated content engine and reviewed by an editor.